You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
For the primary treatment of ovarian cancer in combination with a platinum agent; For the treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy; For the treatment of non-small cell lung cancer (NSCLC); For adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; For the treatment of metastatic cancer of the breast, in combination with trastuzumab (Herceptin) in patients who have tumours that ocer-express HER-2 and who have not received previous chemotherapy for their metastatic disease.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy. For the treatment of ovarian cancer in combination with a platinum agent. INDICATIONS AS AT 28 FEBRUARY 2000: For the primary treatment of ovarian cancer in combination with a platinum agent; for the treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy; for the treatment of non-small cell lung cancer (NSCLC). INDICATIONS AS AT 20 NOVEMBER 2000: For the primary treatment of ovarian cancer in combination with a platinum agent. For the treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy. For the treatment of non-small cell lung cancer (NSCLC). For the adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. INDICATIONS AS AT14 November 2002: Anzatax Injection Concentrate is indicated for the primary treatment of ovarian cancer in combination with a platinum agent. Anzatax Injection Concentrate is indicated for the treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy. Anzatax Injection Concentrate is indicated for the treatment of non-small cell lung cancer (NSCLC). Anzatax Injection Concentrate is indicated for adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. Anzatax is indicated for the treatment of metastatic cancer of the breast, in combination with trastuzumab (Herceptin), in patients who have tumours that over-express HER-2 and who have not received previous chemotherapy for their metastatic disease.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy. For the treatment of ovarian cancer in combination with a platinum agent. INDICATIONS AS AT 28 FEBRUARY 2000: For the primary treatment of ovarian cancer in combination with a platinum agent; for the treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy; for the treatment of non-small cell lung cancer (NSCLC). INDICATIONS AS AT 20 NOVEMBER 2000: For the primary treatment of ovarian cancer in combination with a platinum agent. For the treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy. For the treatment of non-small cell lung cancer (NSCLC). For the adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. INDICATIONS AS AT14 November 2002: Anzatax Injection Concentrate is indicated for the primary treatment of ovarian cancer in combination with a platinum agent. Anzatax Injection Concentrate is indicated for the treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy. Anzatax Injection Concentrate is indicated for the treatment of non-small cell lung cancer (NSCLC). Anzatax Injection Concentrate is indicated for adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide. Anzatax is indicated for the treatment of metastatic cancer of the breast, in combination with trastuzumab (Herceptin), in patients who have tumours that over-express HER-2 and who have not received previous chemotherapy for their metastatic disease.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
For the primary treatment of ovarian cancer in combination with a platinum agent; For the treatment of metastatic ovarian cancer and metastatic breast cancer, after failure of standard therapy; For the treatment of non-small cell lung cancer (NSCLC); For adjuvant treatment of node-positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; For the treatment of metastatic cancer of the breast, in combination with trastuzumab (Herceptin) in patients who have tumours that ocer-express HER-2 and who have not received previous chemotherapy for their metastatic disease.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
